IL166277A0 - Aryl substituted hydantoin compounds and their useas sodium channel blockers - Google Patents
Aryl substituted hydantoin compounds and their useas sodium channel blockersInfo
- Publication number
- IL166277A0 IL166277A0 IL16627705A IL16627705A IL166277A0 IL 166277 A0 IL166277 A0 IL 166277A0 IL 16627705 A IL16627705 A IL 16627705A IL 16627705 A IL16627705 A IL 16627705A IL 166277 A0 IL166277 A0 IL 166277A0
- Authority
- IL
- Israel
- Prior art keywords
- useas
- aryl substituted
- sodium channel
- channel blockers
- substituted hydantoin
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 title 1
- 150000001469 hydantoins Chemical class 0.000 title 1
- 239000003195 sodium channel blocking agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39943502P | 2002-07-31 | 2002-07-31 | |
| PCT/US2003/023827 WO2004010950A2 (en) | 2002-07-31 | 2003-07-31 | Aryl substituted hydantoin compounds and their use as sodium channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL166277A0 true IL166277A0 (en) | 2006-01-15 |
Family
ID=31188583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16627705A IL166277A0 (en) | 2002-07-31 | 2005-01-13 | Aryl substituted hydantoin compounds and their useas sodium channel blockers |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20040097569A1 (de) |
| EP (1) | EP1542686A4 (de) |
| JP (1) | JP2005538101A (de) |
| KR (1) | KR20050026023A (de) |
| CN (1) | CN1671387A (de) |
| AU (1) | AU2003259307A1 (de) |
| BR (1) | BR0313084A (de) |
| CA (1) | CA2492210A1 (de) |
| IL (1) | IL166277A0 (de) |
| MX (1) | MXPA05000813A (de) |
| WO (1) | WO2004010950A2 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0701016B1 (pt) * | 2007-05-03 | 2021-10-26 | Universidade Federal De Pernambuco | Moléculas com atividade analgésica, sedativa e adjuvante de anestésicos |
| CN101255136B (zh) * | 2008-03-11 | 2011-08-17 | 武汉大学 | 5-环丙烷螺环乙内酰脲衍生物及其制备方法和应用 |
| RU2012114770A (ru) | 2009-09-04 | 2013-10-10 | Вандербилт Юниверсити | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
| JP2013531687A (ja) | 2010-07-16 | 2013-08-08 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのピリジン化合物 |
| AU2011303597A1 (en) | 2010-09-17 | 2013-04-11 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
| KR20130095772A (ko) | 2010-10-05 | 2013-08-28 | 퍼듀 퍼머 엘피 | 나트륨 채널 차단제로서 퀴나졸린 화합물 |
| EP2655330B1 (de) | 2010-12-22 | 2016-02-10 | Purdue Pharma LP | Substutuierte pyridine als kaliumkanalblocker |
| EP3255041A1 (de) | 2011-09-02 | 2017-12-13 | Purdue Pharma L.P. | Pyrimidine als natriumkanalblocker |
| WO2013064883A1 (en) | 2011-10-31 | 2013-05-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
| WO2013064884A1 (en) | 2011-10-31 | 2013-05-10 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
| US9133131B2 (en) | 2011-11-15 | 2015-09-15 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
| WO2013136170A1 (en) | 2012-03-16 | 2013-09-19 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| EP2935257B1 (de) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclische sulfonamide als natriumkanalblocker |
| US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
| WO2014135955A1 (en) | 2013-03-04 | 2014-09-12 | Purdue Pharma L.P. | Pyrimidine carboxamides as sodium channel blockers |
| CA2939549C (en) | 2013-03-15 | 2020-08-18 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
| CN105612152A (zh) | 2013-08-26 | 2016-05-25 | 普渡制药公司 | 氮杂螺[4.5]癸烷衍生物及其用途 |
| US9340504B2 (en) | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
| US9745287B2 (en) | 2013-12-20 | 2017-08-29 | Purdue Pharma L.P. | Pyrimidines and use thereof |
| US9695144B2 (en) | 2013-12-23 | 2017-07-04 | Purdue Pharma L.P. | Dibenzazepine derivatives and use thereof |
| JP6337124B2 (ja) | 2013-12-23 | 2018-06-06 | パーデュー、ファーマ、リミテッド、パートナーシップ | インダゾール及びその使用 |
| EP3089978B1 (de) | 2013-12-30 | 2018-08-29 | Purdue Pharma L.P. | Pyridonsulfonmorphinan-analoga als opioidrezeptorliganden |
| JP6526023B2 (ja) | 2014-01-24 | 2019-06-05 | パーデュー、ファーマ、リミテッド、パートナーシップ | ピリジン類及びピリミジン類並びにその使用 |
| AU2015217185B2 (en) | 2014-02-12 | 2018-04-05 | Purdue Pharma L.P. | Isoquinoline derivatives and use thereof |
| US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
| CA2948144A1 (en) | 2014-05-06 | 2015-11-12 | Purdue Pharma L.P. | Benzomorphan analogs and use thereof |
| WO2015192039A1 (en) | 2014-06-13 | 2015-12-17 | Purdue Pharma L.P. | Heterocyclic morphinan derivatives and use thereof |
| MA40171A (fr) | 2014-06-13 | 2017-04-19 | Purdue Pharma Lp | Dérivés d'azamophinan et leur utilisation |
| WO2018125716A1 (en) | 2017-01-02 | 2018-07-05 | Purdue Pharma L.P. | Morphinan derivatives and use thereof |
| CN116354923B (zh) * | 2021-12-27 | 2025-05-09 | 江苏恩华药业股份有限公司 | 一种含氮杂环化合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3903053A (en) * | 1973-11-20 | 1975-09-02 | Teijin Ltd | Process for the preparation of polymers containing divalent hydantoin rings in their main chains |
| US5852029A (en) * | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| US5145862A (en) * | 1990-08-16 | 1992-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of resisting neurodegenerative disorders |
| DE4107857A1 (de) * | 1991-03-12 | 1992-09-17 | Thomae Gmbh Dr K | Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5852192A (en) * | 1992-03-11 | 1998-12-22 | Dr. Karl Thomae Gmbh | Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them |
| KR19990012061A (ko) * | 1997-07-26 | 1999-02-25 | 성재갑 | 파네실 전이효소 저해제로 유용한 하이덴토인 유도체 |
-
2003
- 2003-07-31 US US10/630,814 patent/US20040097569A1/en not_active Abandoned
- 2003-07-31 KR KR1020057001494A patent/KR20050026023A/ko not_active Withdrawn
- 2003-07-31 MX MXPA05000813A patent/MXPA05000813A/es not_active Application Discontinuation
- 2003-07-31 EP EP03772100A patent/EP1542686A4/de not_active Withdrawn
- 2003-07-31 WO PCT/US2003/023827 patent/WO2004010950A2/en not_active Ceased
- 2003-07-31 BR BR0313084-3A patent/BR0313084A/pt not_active Application Discontinuation
- 2003-07-31 JP JP2004524207A patent/JP2005538101A/ja active Pending
- 2003-07-31 CN CNA038183684A patent/CN1671387A/zh active Pending
- 2003-07-31 AU AU2003259307A patent/AU2003259307A1/en not_active Abandoned
- 2003-07-31 CA CA002492210A patent/CA2492210A1/en not_active Abandoned
-
2005
- 2005-01-13 IL IL16627705A patent/IL166277A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003259307A1 (en) | 2004-02-16 |
| KR20050026023A (ko) | 2005-03-14 |
| EP1542686A4 (de) | 2006-10-18 |
| EP1542686A2 (de) | 2005-06-22 |
| BR0313084A (pt) | 2005-06-28 |
| WO2004010950A2 (en) | 2004-02-05 |
| CN1671387A (zh) | 2005-09-21 |
| JP2005538101A (ja) | 2005-12-15 |
| US20040097569A1 (en) | 2004-05-20 |
| WO2004010950A3 (en) | 2004-05-06 |
| CA2492210A1 (en) | 2004-02-05 |
| MXPA05000813A (es) | 2005-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL166277A0 (en) | Aryl substituted hydantoin compounds and their useas sodium channel blockers | |
| PL377087A1 (pl) | Związki heterocykliczne | |
| EP1558585A4 (de) | Neurologisch aktive verbindungen | |
| GB0217786D0 (en) | Compounds | |
| GB0200283D0 (en) | Compounds | |
| EP1476425A4 (de) | Heterocyclische arylsulfonamidobenzyl verbindungen | |
| PL397821A1 (pl) | Związek1-acetylo-6-fluoro-2-indolinon | |
| GB0204241D0 (en) | Compound | |
| AU2003216859A8 (en) | Amidoacetonitrile compounds | |
| GB0210762D0 (en) | Compounds | |
| GB0207323D0 (en) | Compounds | |
| GB0224830D0 (en) | Compound | |
| GB0216383D0 (en) | Compounds | |
| GB0203778D0 (en) | Compounds | |
| GB0213027D0 (en) | Compound | |
| GB0213011D0 (en) | Compounds | |
| GB0213122D0 (en) | Compounds | |
| AU2003275480A8 (en) | Compounds | |
| GB0203811D0 (en) | Compounds | |
| SI1485359T1 (sl) | Blokatorji natrijevega kanala | |
| TW538684U (en) | Improved structure of conveyor calender | |
| GB0229075D0 (en) | Compound | |
| GB0229576D0 (en) | Compound | |
| GB0217506D0 (en) | Compound | |
| GB0214267D0 (en) | Compound |